|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0009429,
umls-concept:C0011860,
umls-concept:C0025598,
umls-concept:C0030705,
umls-concept:C0087111,
umls-concept:C0205265,
umls-concept:C0205318,
umls-concept:C0289313,
umls-concept:C0556895,
umls-concept:C1555582,
umls-concept:C1707455
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2006-10-9
|
|
pubmed:abstractText |
This study assessed the efficacy and safety of rosiglitazone and metformin (RSG/MET) fixed-dose combination (AVANDAMET) as initial therapy in patients with uncontrolled type 2 diabetes compared with monotherapy with either RSG or MET after 32 weeks of treatment.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/Hemoglobin A, Glycosylated,
http://linkedlifedata.com/resource/pubmed/chemical/Hypoglycemic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin,
http://linkedlifedata.com/resource/pubmed/chemical/Lipids,
http://linkedlifedata.com/resource/pubmed/chemical/Metformin,
http://linkedlifedata.com/resource/pubmed/chemical/Thiazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Thiazolidinediones,
http://linkedlifedata.com/resource/pubmed/chemical/rosiglitazone,
http://linkedlifedata.com/resource/pubmed/chemical/rosiglitazone-metformin combination
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1462-8902
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
650-60
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17026489-Adolescent,
pubmed-meshheading:17026489-Adult,
pubmed-meshheading:17026489-Aged,
pubmed-meshheading:17026489-Blood Glucose,
pubmed-meshheading:17026489-Diabetes Mellitus, Type 2,
pubmed-meshheading:17026489-Double-Blind Method,
pubmed-meshheading:17026489-Drug Combinations,
pubmed-meshheading:17026489-Female,
pubmed-meshheading:17026489-Hemoglobin A, Glycosylated,
pubmed-meshheading:17026489-Humans,
pubmed-meshheading:17026489-Hypoglycemic Agents,
pubmed-meshheading:17026489-Insulin,
pubmed-meshheading:17026489-Insulin Resistance,
pubmed-meshheading:17026489-Lipids,
pubmed-meshheading:17026489-Male,
pubmed-meshheading:17026489-Metformin,
pubmed-meshheading:17026489-Middle Aged,
pubmed-meshheading:17026489-Thiazoles,
pubmed-meshheading:17026489-Thiazolidinediones,
pubmed-meshheading:17026489-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
|
|
pubmed:affiliation |
Dallas Diabetes and Endocrine Center, Dallas, TX 75230, USA. juliorosenstock@dallasdiabetes.com
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
